Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M7,755Revenue $M1,289Net Margin (%)26.4Z-Score10.2
Enterprise Value $M7,186EPS $6.3Operating Margin %41.8F-Score8
P/E(ttm))26.9Cash Flow Per Share $4.9Pre-tax Margin (%)40.8Higher ROA y-yY
Price/Book6.310-y EBITDA Growth Rate %0Quick Ratio1.8Cash flow > EarningsY
Price/Sales6.75-y EBITDA Growth Rate %55.8Current Ratio1.9Lower Leverage y-yY
Price/Cash Flow10.6y-y EBITDA Growth Rate %68.6ROA % (ttm)16.8Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)27.6Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M46.7ROI % (ttm)20.2Gross Margin Increase y-yY

Gurus Latest Trades with UTHR

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
UTHRJean-Marie Eveillard 2014-12-31 Add0.03%$122.11 - $134.8
($128.83)
$ 166.1822%Add 37.43%360,180
UTHRJoel Greenblatt 2014-09-30 Reduce-0.4%$86.44 - $136.16
($102.87)
$ 166.1838%Reduce -55.36%288,401
UTHRJean-Marie Eveillard 2014-09-30 Buy 0.08%$86.44 - $136.16
($102.87)
$ 166.1838%New holding262,080
UTHRJoel Greenblatt 2014-06-30 Add0.37%$86.14 - $107.81
($96.29)
$ 166.1842%Add 104.14%646,066
UTHRJoel Greenblatt 2014-03-31 Add0.17%$90.67 - $113.39
($102.75)
$ 166.1838%Add 62.64%316,489
UTHRJoel Greenblatt 2013-12-31 Reduce-0.45%$80.03 - $114.51
($89.93)
$ 166.1846%Reduce -47.71%194,595
UTHRVanguard Health Care Fund 2013-09-30 Sold Out -0.32%$66.1 - $79.58
($73.08)
$ 166.1856%Sold Out0
UTHRDavid Dreman 2013-09-30 Sold Out -0.12%$66.1 - $79.58
($73.08)
$ 166.1856%Sold Out0
UTHRJoel Greenblatt 2013-06-30 Add0.13%$59.64 - $69.31
($64.42)
$ 166.1861%Add 15.34%341,330
UTHRJoel Greenblatt 2013-03-31 Add0.02%$51.64 - $62.57
($56.61)
$ 166.1866%Add 2.24%295,921
UTHRVanguard Health Care Fund 2013-03-31 Reduce-0.02%$51.64 - $62.57
($56.61)
$ 166.1866%Reduce -11.23%1,320,000
UTHRDavid Dreman 2013-03-31 Reduce$51.64 - $62.57
($56.61)
$ 166.1866%Reduce -2.46%55,625
UTHRDavid Dreman 2012-12-31 Buy 0.09%$44.99 - $58.91
($52.11)
$ 166.1869%New holding57,025
UTHRHOTCHKIS & WILEY 2012-12-31 Sold Out -0.09%$44.99 - $58.91
($52.11)
$ 166.1869%Sold Out0
UTHRJoel Greenblatt 2012-12-31 Add0.03%$44.992 - $58.91
($52.13)
$ 166.1869%Add 3.34%289,442
UTHRVanguard Health Care Fund 2012-12-31 Reduce-0.03%$44.992 - $58.91
($52.13)
$ 166.1869%Reduce -6.30%1,487,000
UTHRJoel Greenblatt 2012-09-30 Reduce-0.19%$49.87 - $58.3
($54.58)
$ 166.1867%Reduce -15.82%280,089
UTHRHOTCHKIS & WILEY 2012-09-30 Add0.06%$49.73 - $58.2
($54.16)
$ 166.1867%Add 270.56%266,800
UTHRVanguard Health Care Fund 2012-09-30 Reduce-0.05%$49.87 - $58.3
($54.58)
$ 166.1867%Reduce -11.19%1,587,000
UTHRJoel Greenblatt 2012-06-30 Add0.6%$41.19 - $49.51
($44.12)
$ 166.1873%Add 101.59%332,744
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

UTHR is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


UTHR: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ROTHBLATT MARTINE AChairman & Co-CEO 2015-04-22Sell2,211$187.490.57view
JEFFS ROGERPresident & Co-CEO 2015-04-21Sell10,000$187.860.37view
ROTHBLATT MARTINE AChairman & Co-CEO 2015-04-20Sell2,592$184.862view
MAHON PAUL AEVP & General Counsel 2015-04-16Sell6,000$187.910.35view
ROTHBLATT MARTINE AChairman & Co-CEO 2015-04-16Sell11,873$187.010.83view
JEFFS ROGERPresident & Co-CEO 2015-04-14Sell10,000$185.821.47view
ZACCARDELLI DAVIDEVP & COO 2015-04-14Sell3,250$185.821.47view
ROTHBLATT MARTINE AChairman & Co-CEO 2015-04-13Sell2,592$187.860.37view
ZACCARDELLI DAVIDEVP & COO 2015-04-09Sell4,000$184.842.01view
ROTHBLATT MARTINE AChairman & Co-CEO 2015-04-09Sell9,662$183.092.99view

Press Releases about UTHR :

    Quarterly/Annual Reports about UTHR:

    News about UTHR:

    Articles On GuruFocus.com
    FDA Approval Of Cancer Drug Catapults United Therapeutics Shares By 2% Mar 11 2015 
    Weekly CFO Sells Highlight: United Therapeutics Corp, Williams Companies Inc, Facebook Inc. Oct 12 2014 
    Here are 5 Good Companies to Consider Investing In Right Now Feb 11 2014 
    High-Dollar Insider Sells - Zuckerberg Sells 41M Facebook Shares Dec 27 2013 
    John Hussman's Third Quarter Top 5 Nov 07 2013 
    Vanguard Health Care Fund Selling Update Oct 30 2013 
    comment on UTHR May 11 2013 
    Super-Fast Growing Mid-Cap Growth Stocks with Explosive Returns May 09 2013 
    5 Fast-Growing Small-Cap Stocks to Watch Mar 26 2013 
    comment on UTHR Mar 23 2013 


    More From Other Websites
    Will Biogen's (BIIB) Earnings Streak Continue in 1Q? - Analyst Blog Apr 23 2015
    Twitter’s latest shareholder slap: $73 million for a finance guy Apr 22 2015
    United Therapeutics Corporation To Announce First Quarter 2015 Financial Results Before Market Open... Apr 21 2015
    United Therapeutics Corporation To Announce First Quarter 2015 Financial Results Before Market Open... Apr 21 2015
    United Therapeutics Corporation (UTHR), Amgen, Inc. (AMGN): Neil Shah’s Top Healthcare Picks... Apr 16 2015
    MedImmune, Tech Council of Maryland chart path for region's biotech community Mar 30 2015
    Era Group Inc (ERA), BioMarin Pharmaceutical Inc. (BMRN), & Assured Guaranty Ltd. (AGO) Among Stocks... Mar 27 2015
    United Therapeutics (UTHR) Crumbles: Stock Falls by 6.5% - Tale of the Tape Mar 26 2015
    Palo Alto Rejoicing at ABIOMED, Inc. (ABMD)’s 18% Spike Mar 25 2015
    Retrophin Soars on FDA Approval of Bile Acid Disorder Drug - Analyst Blog Mar 19 2015
    Akorn, Inc. (AKRX), United Therapeutics Corporation (UTHR) Among Consonance Capital’s Winning Bets... Mar 19 2015
    To sell or not to sell: United Therapeutics faces choice with potential fast-track drug voucher Mar 18 2015
    SteadyMed hopes to break Bay Area IPO lull with $68.4M offering this week Mar 17 2015
    Watch these drug stocks Monday Mar 13 2015
    These new meds could move stocks Mar 13 2015
    The Zacks Analyst Blog Highlights: AbbVie, Pharmacyclics, Amgen, United Therapeutics and Regeneron -... Mar 12 2015
    United Therapeutics upgraded by Argus Mar 12 2015
    United Therapeutics' High-Risk Cancer Drug Wins FDA Nod - Analyst Blog Mar 11 2015
    United Therapeutics Mar 10 2015
    United Therapeutics Wins FDA Nod, Priority Voucher Mar 10 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK